SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice

Published: 12 November 2021

  • Views:

    Views Icon 4024
  • Likes:

    Heart Icon 4

Overview

Full programme

  • Views:

    Views Icon 4024
  • Likes:

    Heart Icon 4

Overview

Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) and Prof Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice.

 

This three-part series, 'SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice', brings together three experts to review the implications for pathophysiology, screening and treatment strategies.

This programme is supported by an unrestricted educational grant from AstraZeneca

Learning Objectives

  • Recall the existing relationship between chronic kidney disease and cardiovascular disease for patients with and without type 2 diabetes.
  • Consider the global burden of CKD, including for patients with type 2 diabetes, and be aware of existing guidelines for screening.
  • Review treatment options for the treatment of patients with chronic kidney disease, and the role of SGLT2i therapies in available strategies.

Target Audience

  • Cardiologists
  • Endocrinologists
  • Renal specialists

Series overview

Part 1

Cardio-renal Pathophysiology

Prof Khunti outlines key takeaways of what clinicians need to know about the relationship between chronic kidney disease and cardiovascular disease, and considers whether that differs in patients living with and without type 2 diabetes. Prof Heerspink addresses why clinicians should be encouraged to intervene early for patients living with CKD to attain improved cardiovascular and kidney outcomes.

1 session

Part 2

Screening for CKD

Prof Khunti addresses the burden of CKD globally, including the prevalence of CKD in patients with type 2 diabetes. Dr Zieroth asks the faculty about existing tools for screening for CKD, and the recommendations of international guidelines.

1 session

Part 3

Treatment Options in CKD

In this final part, moderator Dr Zieroth enquires of the latest treatment options for CKD, with Prof Heerspink advising on evidence supporting the use of treatments, whilst Prof Khunti provides insight to the role of initiating SGLT2 therapy, and underlines the urgency to treat.

1 session

Faculty biographies